Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 05/01 | 05/04 | 13,761 sh2 trades | $8.40avg. | $115,610.36 | −12.0% | |
Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 05/01 | 05/04 | 15,481 sh2 trades | $8.40avg. | $129,993.56 | −10.7% | |
Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 05/01 | 05/04 | 17,202 sh2 trades | $8.40avg. | $144,453.49 | −17.7% | |
Keith KatkinDirector | Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 04/30 | 05/04 | 15,481 sh | $8.28 | $128,182.68 | −13.9% |
Paul Anthony WilliamsSVP, Products Business | Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 04/01 | 04/03 | 4,000 sh | $8.44 | $33,760 | −6.0% |
Emergent BioSolutionsEBS | Open-market sale | 25/12/05 | 25/12/09 | 21,984 sh2 trades | $11.97avg. | $263,100.6 | −18.3% | |
Donald W. DeGolyerDirector | Emergent BioSolutionsEBS | Open-market sale | 25/11/10 | 25/11/12 | 17,801 sh | $10.54 | $187,622.54 | −12.9% |
Sujata Tyagi DayalDirector | Emergent BioSolutionsEBS | Open-market sale | 25/11/07 | 25/11/10 | 8,552 sh | $10.00 | $85,520 | −8.8% |
Coleen GlessnerEVP, Quality & Ethics, and CPL | Emergent BioSolutionsEBS | Open-market sale | 25/10/07 | 25/10/16 | 30,608 sh | $10.00 | $306,080 | −17.5% |
Kathryn C. ZoonDirector | Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 25/08/15 | 25/08/18 | 7,086 sh | $8.87 | $62,852.82 | −9.0% |
Donald W. DeGolyerDirector | Emergent BioSolutionsEBS | Open-market sale | 25/08/12 | 25/08/13 | 7,844 sh | $8.65 | $67,850.6 | −5.4% |
Keith KatkinDirector | Emergent BioSolutionsEBS | Open-market sale10b5-1 plan | 25/05/23 | 25/05/28 | 7,844 sh | $6.30 | $49,417.2 | −8.3% |
Joseph C. PapaPresident and CEO | Emergent BioSolutionsEBS | Open-market buy | 25/05/13 | 25/05/15 | 60,000 sh | $5.83 | $349,800 | +21.2% |
Fowler Neal FranklinDirector | Emergent BioSolutionsEBS | Open-market sale | 25/03/12 | 25/03/12 | 35,000 sh | $5.83 | $204,050 | −25.7% |
Kathryn C. ZoonDirector | Emergent BioSolutionsEBS | Open-market sale | 25/03/12 | 25/03/12 | 10,000 sh | $5.73 | $57,300 | −18.4% |
Donald W. DeGolyerDirector | Emergent BioSolutionsEBS | Open-market sale | 24/11/12 | 24/11/14 | 25,000 sh | $10.91 | $272,750 | −18.4% |
Marvin L. WhiteDirector | Emergent BioSolutionsEBS | Open-market sale | 24/11/11 | 24/11/13 | 14,287 sh | $11.97 | $171,015.39 | −20.9% |
Kathryn C. ZoonDirector | Emergent BioSolutionsEBS | Open-market sale | 24/06/04 | 24/06/06 | 10,000 sh | $6.11 | $61,100 | −15.5% |
Kathryn C. ZoonDirector | Emergent BioSolutionsEBS | Open-market sale | 24/05/29 | 24/05/31 | 1,830 sh | $4.61 | $8,436.3 | −2.8% |
Kathryn C. ZoonDirector | Emergent BioSolutionsEBS | Open-market sale | 24/05/21 | 24/05/23 | 1,089 sh | $5.78 | $6,294.42 | −2.2% |